-
The winter baby killer has a nemesis! The first drug available for respiratory syncytial virus infection in infants on the domestic market
On January 2nd, AstraZeneca and Sanofi jointly developed a long-acting monoclonal antibody called Nirsevimab, which was officially approved for marketing by the National Medical Products Administrati ...